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Genetic Defects in Surfactant Protein A2
Are Associated with Pulmonary Fibrosis
and Lung Cancer
Yongyu Wang,1 Phillip J. Kuan,1,2 Chao Xing,1 Jennifer T. Cronkhite,1 Fernando Torres,2
Randall L. Rosenblatt,2 J. Michael DiMaio,3 Lisa N. Kinch,4 Nick V. Grishin,4,5
and Christine Kim Garcia1,2,*
Idiopathic pulmonary ﬁbrosis (IPF) is a lethal scarring lung disease that affects older adults. Heterozygous rare mutations in the genes
encoding telomerase are found in ~15% of familial cases. We have used linkage to map another disease-causing gene in a large family
with IPF and adenocarcinoma of the lung to a 15.7 Mb region on chromosome 10.We identiﬁed a rare missensemutation in a candidate
gene, SFTPA2, within the interval encoding surfactant protein A2 (SP-A2). Another rare mutation in SFTPA2 was identiﬁed in another
family with IPF and lung cancer. Bothmutations involve invariant residues in the highly conserved carbohydrate-recognition domain of
the protein and are predicted to disrupt protein structure. Recombinant proteins carrying these mutations are retained in the endo-
plasmic reticulum and are not secreted. These data are consistent with SFTPA2 germlinemutations that interfere with protein trafﬁcking
and cause familial IPF and lung cancer.Idiopathic pulmonary ﬁbrosis (IPF, MIM 178500) is a scar-
ring lung disease that presents in older adults with short-
ness of breath and cough. The mean length of time from
disease diagnosis to death is only 3 years. IPF is distin-
guished by its progressive course, radiographic features,
and pathologic evidence of patchy injury with foci of repli-
cating ﬁbroblasts at the interface of normal and scarred
lung tissue.1 Approximately 2% of subjects with IPF have
a familial disease form characterized by an autosomal-
dominant pattern of inheritance with incomplete pene-
trance.2 In ~15% of these families, the disease is caused
by mutations in the genes encoding the protein (TERT,
MIM 187270) or RNA component (TERC, MIM 602322)
of telomerase,3,4 an enzyme that maintains the integrity
of the chromosomal ends. An additional 25% of individ-
uals who have either familial or sporadic pulmonary
ﬁbrosis but who do not have a mutation in TERT or
TERC have evidence of telomere shortening of circulating
leukocytes.5 Although evidence of telomerase dysfunction
is present in a large proportion of IPF cases, other genetic
defects probably cause disease.
We have 59 kindreds who have familial pulmonary
ﬁbrosis and no identiﬁable mutations in the coding
regions of TERT or TERC. To identify other genes that are
defective in IPF, we performed a whole-genome linkage
study in one of the largest of these families in our collec-
tion. The study was approved by the Institutional Review
Board of the University of Texas Southwestern Medical
Center at Dallas. Kindreds were described previously.5
Written informed consent was obtained from all subjects.
Genomic DNA was isolated from either circulating leuko-
cytes or parafﬁn-embedded archived tissue.452 The American Journal of Human Genetics 84, 52–59, January 9, 2In family F27, multiple members have early-onset
pulmonary ﬁbrosis and lung cancer cosegregating in an
autosomal-dominant pattern, suggesting that these two
diseases share a common etiology. The proband of the
family, subject IV:8 (Figure 1), is a 51-year-old white man
who has ten relatives with pulmonary ﬁbrosis; ﬁve of the
ten died before age 50. Four individuals (III:8, III:12, IV:2,
and IV:7) also had adenocarcinoma of the lung with
features of bronchioloalveolar cell carcinoma (BAC). Three
other related individuals had pulmonary adenocarcinoma
or BAC in the absence of known ﬁbrosis. Photomicro-
graphs of hematoxylin and eosin-stained slides of resected
lung tissue from affected family members are shown in
Figure 2. Seven individuals, including the proband, were
evaluated with pulmonary function testing and high-reso-
lution CT scans of the chest; medical records or death
certiﬁcates were obtained when possible. Additional clin-
ical information is provided in Table S1.
We performed a whole genome linkage analysis of 29
family members by using the Illumina Linkage IVb SNP
panel of >6,000 SNPs. Call rates varied from 97.2% to
98.5% for Autopure-puriﬁed DNA and from 56.4% to
73.9% for whole-genome-ampliﬁed DNA extracted from
archived samples. Individuals with pulmonary ﬁbrosis
and/or lung cancer were classiﬁed as ‘‘affected,’’ and all
others were assigned an unknown affectation status. We
used the software MERLIN6 to screen the entire genome
by using multipoint model-free linkage analysis,7 and we
then evaluated the regions with the highest signals by
using a model-based method. Figure S1 in the Supple-
mental Data shows the analysis of family F27 with the
highest peak on chromosome 10; the model-free LOD1Eugene McDermott Center for Human Growth and Development, 2Department of Internal Medicine, 3Department of Cardiovascular and Thoracic
Surgery, 4Department of Biochemistry, 5Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
*Correspondence: christine.garcia@utsouthwestern.edu
DOI 10.1016/j.ajhg.2008.11.010. ª2009 by The American Society of Human Genetics. All rights reserved.009
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Rhesus monkey SFTPA2     AYVGLTEGPSPGDFRYSDGTPVNYTNWYPGEPAGRGTEQCVEMYTDGRWNDRNCLYNRLTICEF   
Rhesus monkey SFTPA1     AYVGLTEGPSPGDFRYSDGTPVNYTNWYPGEPAGRGTEQCVEMYTDGRWNDRNCLYNRLTICEF   
Lemur                    AYLGLAEGPTPGDFRYLDGAPVNYSNWYPGEPGGRGKEKCVEMYADGQWNDKNCLQYRLAICEF   
Elephant                 AYLGLAEGSTPGEFYYLDGAPVNYTNWYLGEPRGLGKERCVEMYTDGQWNDKNCLQHRLTICEF   
Armadillo                AYLGLAEGPTPGEFRQLDGAPVNYTNWYPGEPRGRGKERCVDMYTDGQWNDKNCLQYRLAICEF   
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Figure 1. Mutations in SFTPA2 Segregate with Familial Lung Cancer and Pulmonary Fibrosis
(A) Abridged pedigrees are shown. The arrow indicates the index case. Circles represent females; squares represent males. Symbols with
a slash through them indicate deceased subjects. Individuals with pulmonary fibrosis, lung cancer, or undefined lung disease are indi-
cated by blue, red, and green symbols, respectively. Numbers below each symbol correspond to the individuals described in Table S1;
numbers in parentheses indicate individuals for whom no DNA sample was available. The presence or absence of a mutation in SFTPA2
is indicated by plus or minus signs, respectively. When the mutation was inferred based upon the pattern of inheritance, the plus
sign is placed in parentheses. The current age or the age at death is indicated to the upper right of each symbol. The SFTPA2 mutations
and predicted amino acid changes are listed above each family.
(B) A region of chromosome 10 cosegregates with pulmonary fibrosis and lung cancer. The genes that encode paralogs of both surfactant
protein A and surfactant protein D lie within the linked region. The DNA sequence of a segment of SFTPA2 exon 6 is shown for the hetero-
zygous CKG810 (left) and the proband of family F27 (right). A single base substitution (arrow) changes the wild-type thymidine to cyto-
sine and leads to the predicted substitution of phenylalanine to serine at codon 198 (left); substitution of the wild-type guanine to
thymidine leads to the predicted substitution of glycine for valine at codon 231 (right). Both mutations affect the coding region of
the carbohydrate-recognition domain of surfactant protein A2.
(C) The terminal portion of the amino acid sequence of the carbohydrate-recognition domain of surfactant A proteins is shown from
diverse vertebrate species. This domain is highly conserved. Both the phenylalanine and glycine at positions 198 and 231, respectively,
are conserved in all species shown. All sequences were obtained from NCBI; the comparison of the different proteins was based on a Clus-
talW-generated alignment.
(D) The ribbon diagram of the crystal structure of the monomeric carbohydrate recognition domain (CRD) and neck domains of rat surfac-
tant protein A is shown; the positions of amino acids corresponding to codons 198 and 231 of the human sequence are indicated by
arrows.score is 3.22 (p value ¼ 6.0 3 105), and the model-based
LOD score is 2.74 (p value < 1.8 3 103) as determined
in a dominant genetic model with a penetrance of 0.95.
All affected family members share an identical-by-descent
15.7 Mb region of chromosome 10 (bounded by markers
rs877783 and rs4869, Figure S2). Additional polymorphic
microsatellite markers within this region were genotyped,
and haplotypes were determined by MERLIN.The AApproximately 118 annotated genes, including the
genes encoding surfactant proteins A and D, reside within
the linked interval. These two genes were considered excel-
lent candidates because they are both expressed at high
levels in the lung and play key roles in maintaining the
integrity of the air spaces (alveoli) of the lung. Surfactant
A has two isoforms, SP-A1 and SP-A2, which are encoded
by adjacent genes (SFTPA1, MIM 178630, and SFTPA2,merican Journal of Human Genetics 84, 52–59, January 9, 2009 53
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Figure 2. Histology and Immunohistochemical Staining of
SP-A in Lung Specimens fromAffected Individuals in Family F27
The hemotoxylin and eosin-stained slides (A–J) show different
pathologic subtypes of pulmonary fibrosis with and without adeno-
carcinoma with features of bronchioloalveolar cell carcinoma
(BAC). Specimens from the proband IV:8 (A, B) and III:11 (C, D)
demonstrate the pathologic findings of usual interstitial pneu-
monia, consistent with IPF. The specimen shown from IV:6
(E and F), a 29-year-old female diagnosed with hypersensitivity
pneumonitis resulting from bird exposures, shows organizing
pneumonitis with minimal fibrosis; her disease remitted with pred-
nisone treatment and avoidance of birds. The specimen from III:12
(G and H) shows pulmonary fibrosis and adenocarcinoma with
features of BAC. An autopsy sample from IV:7 (I and J) shows
extensive severe interstitial fibrosis with cystic remodeling and
marked epithelial proliferation. In some areas the epithelial cells
show severe cytologic atypical and papillary and acinar growth
patterns, consistent with adenocarcinoma with features of BAC
confined to the lungs. Photographs were obtained as previously
described.4 Slides from a normal subject (K), a sporadic patient
with IPF without any mutations in SFTPA2 (L), a patient with
adenocarcinoma with BAC features and no SFTPA2 genomic muta-
tions (N) and F27 family members IV:8 (M), IV:7 (O), and III:12
(P) were stained for immunochemical localization of SP-A. Type
II cells lining the alveoli and neoplastic adenocarcinoma cells
demonstrate SP-A staining (indicated by the brown color). Slides54 The American Journal of Human Genetics 84, 52–59, January 9, 2MIM 178642) that are >98% and >90% identical in their
coding and noncoding regions, respectively. Only four
amino acids differ between the two human proteins. We
selectively ampliﬁed the coding exons and consensus
splicing sequences of SFTPA1 and SFTPA2 for the proband
of family F27 by using gene-speciﬁc oligonucleotides.
Sequencing was then performed as described;4 all PCR
conditions and primers are listed in Table S2. A transver-
sion mutation (GGG / GTG) was identiﬁed in codon
231 of one SFTPA2 allele; this c.692G/ T G231V muta-
tion is predicted to change a highly conserved glycine
residue to a valine (Figure 1B). All individuals in kindred
F27 with pulmonary ﬁbrosis and/or lung cancer were
heterozygous for this mutation (Figure 1A).
SFTPA1 and SFTPA2were then sequenced in the other 58
probands in our collection of families who have pulmo-
nary ﬁbrosis and no mutations in TERT or TERC. A hetero-
zygous transversion mutation (TTC/ TCC) in codon 198
of SFTPA2 was found in a 45-year-old white individual
with IPF and lung cancer. This c.593T/C F198Smutation
substitutes a serine residue for a highly conserved phenyl-
alanine. Although this individual had multiple family
members with pulmonary ﬁbrosis and lung cancer, these
individuals were not available for study.
We used Taqman allelic discrimination assays9 to test for
both SFTPA2 mutations in a large (n ¼ 3557) multiethnic
population-based probability sample of Dallas County;
this sample included 1048 whites.8 The oligonucleotides
used for the assays are listed in Table S3. No other subjects
were found with either of the sequence variants. We also
sequenced the coding exons and consensus splicing
sequences of the gene encoding SP-D in the proband of
family F27 and in 32 other probands. No rare variants
were found. All the DNA sequence variants we identiﬁed
in the genes encoding SP-A1, SP-A2, and SP-D are provided
in Table S4.
Pulmonary surfactant protein A (SP-A) is the major
protein of pulmonary surfactant, a mixture of phospho-
lipids and proteins synthesized by the type II alveolar
epithelial cells. Surfactant stabilizes the gas-exchanging
surface of the alveoli and plays a role in pulmonary host
were deparaffinized with xylene for 10 min two times and rehy-
drated by immersion in serial ethanol baths: 100% twice, 95%
once, 75% once, 50% once, and then three washes in PBS for
5 min each. Antigen retrieval was performed with 13 Citra buffer
(Biogenex, San Ramon, CA) for 10 min at 100C. Endogenous
peroxidase activity was quenched by incubation with 0.6% H2O2
in methanol for 30 min at room temperature. Immunohistochem-
ical staining was performed with the Vectastain Elite ABC kit
(Vector Laboratories) according to the manufacturer’s protocol
with anti-SP-A antibody (1:2000 dilution with overnight incuba-
tion at 4C), biotinylated GAR (1:500 with a 1 hr room-temperature
incubation) and the chromagen DAB (Dako). Slides were counter-
stained with Mayer’s Hematoxylin (Dako, Carpinteria, CA) and
mounted with VectaMount AQ (Vector Laboratories). Scale bars
represent 1 mm and 100 mm for the low-power (A, C, E, G, and I)
and high-power (B, D, F, H, and J–P) magnifications, respectively.009
defense by binding, aggregating and opsonizing various
microorganisms.10,11 SP-A belongs to a structurally homol-
ogous family of innate-immune defense proteins that are
known as collectins and contain a collagen-like N-terminal
region that is involved in trimerization of the protein and
a C-terminal carbohydrate recognition (CRD) lectin
domain.12,13 It assembles into 18-subunit oligomers that
are composed of six disulﬁde-linked trimers assembled in
a ‘‘ﬂower bouquet’’ pattern. Mice that lack SP-A are suscep-
tible to pulmonary infections from multiple organisms
and lack tubular myelin, the ordered lattice-like array of in-
tersecting membranes and proteins in the alveolar space.14
Both of the mutations we identiﬁed in SP-A2 involve
amino acids in the CRD, which is highly conserved among
all surfactant orthologs from Xenopus to humans
(Figure 1C). Both mutations are predicted to disrupt the
tertiary structure of the CRD domain (Figure 1D). The
bulky aromatic ring of phenylalanine at position 198 is
located in the hydrophobic core of the protein, and substi-
tution of a serine at this position would be predicted to
destabilize the protein on the basis of the crystal structure
of the rat protein.15 The glycine at position 231 lies adja-
cent to an alpha helix, and the substitution of a larger
residue such as a valine at this position would be predicted
to result in disruptive steric clashes.
Immunodetectable SP-A was detected in the type II alve-
olar cells via a rabbit polyclonal antibody raised against
puriﬁed human SP-A (a kind gift from C. R. Mendelson);
this antibody does not distinguish between SP-A1 and
SP-A2. The staining of type II cells in the affected indi-
vidual IV:8 in family F27 was similar to the staining of
normal lung or lung tissue from a patient with sporadic
IPF and no mutations in SFTPA2. In both individuals IV:7
and III:12, the adenocarcinoma cells lining the air spaces
demonstrate expression of SP-A (Figure 2), which is charac-
teristic of this type of lung cancer.16
To determine what effect the sequence variations identi-
ﬁed in SP-A2 in this study have on the synthesis and secre-
tion of the protein, we expressed the wild-type and the
variant proteins in A549 cells, an immortalized human
alveolar epithelial cell line derived from a lung adenocarci-
noma. High-ﬁdelity DNA polymerases were used for
cloning, and all subclones were conﬁrmed by sequence
analysis. Full-length human SFTPA1 cDNAwas PCR ampli-
ﬁed from clone LIFESEQ90096303 (Open Biosystems,
Waltham, MA) and subcloned into pcDNA3 (Invitrogen,
Carlsbad, CA) downstream of the CMV promoter. We
used two partial IMAGE cDNA clones, 5184888 and
841707 (Invitrogen), to construct a full-length SFTPA2
cDNA. Site-directed mutagenesis (QuickChange, Strata-
gene) was utilized so that the DNA sequence of wild-type
SP-A1 and SP-A2 clones exactly matched NM_005411.3
and NM_006926.2, respectively. In a parallel set of experi-
ments, we used expression constructs containing an in-
frame 14 amino acid V5-tag immediately after the glutamic
acid at position 21 by primer extension mutagenesis and
zipper PCR.The AA549 cells were transfected with the expression plasmids
as follows: 350,000 cells were plated on 35 mm wells in
2 ml complete medium (Ham’s F12 with 10% FBS and
1% P/S) and transfected on day 1 with 1–2 mg DNA and
with 3 ml FuGENE HD Transfection Reagent (Roche, Basel,
Switzerland) per mg DNA according to the manufacturer’s
protocol. The cells were refed with complete medium on
day 2. Seventy-two hours after transfection, we examined
the cell lysate and medium by immunoblotting to assay
for the presence of SP-A. Onemilliliter of cultured medium
was removed from each well and centrifuged at 16,000 3 g
for 10min at 4C. The cells werewashed oncewith 2ml ice-
cold PBS, harvested in 300 ml of RIPA lysis buffer (150 mM
NaCl, 50 mM Tris-HCl [pH 8], 1 mM EDTA [pH 8], 1%
NP-40, 0.1% SDS, and 0.1% deoxycholate with 1 tablet of
protease cocktail [Roche] per 10 ml buffer), sonicated for
10 s., and centrifuged at 16,000 3 g at 4C for 10 min. The
protein concentration of the medium and cellular lysates
was determined with the BCA Assay (Pierce, Rockford, IL).
Protein aliquots were eletrophoresed on 10% SDS-PAGE
Bio-Rad minigels and transferred to nitrocellulose Protran
membranes (Whatman, Dassel, Germany). The blots
were incubated for 1 hr at room temperature in blocking
buffer (5% dried milk in TBST [150 mM NaCl, 10 mM
Tris (pH 8), 0.1% Tween-20]), incubated with primary anti-
body overnight at a dilution of 1:10,000 (anti-SP-A or anti-
V5 mAb R960-25 from Invitrogen) in blocking buffer,
washed four times in TBST for 5 min each, incubated
with secondary antibody (Southern Biotech; Birmington,
AL) at 1:20,000 in blocking buffer for 1 hr at room temper-
ature, washed four times in TBST for 5min each, and devel-
oped with SuperSignal West Pico Chemiluminescent
substrate (Pierce) according to themanufacturer’s protocol.
In cells expressing either wild-type SP-A or one of the SP-
A variants with an allele frequency >5%, immunoreactive
protein was present in both the cell lysate and the medium
(Figure 3A). In contrast, the SP-A2 G231V and F198S vari-
ants were poorly expressed in the cells, and no protein
was detected in the culture medium (Figure 3A). When
a V5-speciﬁc antibody was used in a parallel set of experi-
ments to analyze cells expressing the V5-tagged constructs,
the protein was readily detected in the cell lysates but not
in the medium. Another rare variant identiﬁed in this
study, SP-A2 L12W, was expressed and secreted in amounts
comparable to the wild-type protein. This variant failed to
cosegregate with pulmonary ﬁbrosis in the family in which
the mutation was identiﬁed.
We also examined all the other rare and common SP-A1
variants that were identiﬁed in this study. All of these
forms of SP-A1 had an expression pattern that was similar
to the wild-type protein (Figure S3).
To determine whether the wild-type SP-A1 or SP-A2 in-
teracted with the G231V and F198S SP-A2 variants, we
coexpressed an in-frame Myc-tagged wild-type SP-A1 or
SP-A2 (three copies of EQKLISEEDLN engineered after
the signal peptide as described above) with the V5-tagged
SP-A2 variants and immunoprecipitated the cellular lysatesmerican Journal of Human Genetics 84, 52–59, January 9, 2009 55
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Figure 3. The Effects of the G231V and F198S SFTPA2 Muta-
tions on Protein Expression, Secretion, Interactions, and Endo-
glycosidase Sensitivity in Transiently Transfected A549 Cells
(A) A549 cells were transiently transfected with vector plasmid
(Mock), the wild-type SP-A2 expression construct and various
untagged SP-A2 constructs (upper panels) or V5-tagged constructs
(lower panels). Rare variants are those that were found at
a frequency of <5%. Aliquots of cellular lysates (C, 40 mg) and
medium (M, 80 mg) were analyzed via immunoblotting with either
a rabbit polyclonal that was raised against purified human SP-A
(upper panel) or a mouse monoclonal antibody that recognizes
the V5 epitope (lower panel). Blots were exposed for 1–20 min
or 1–20 s for the anti-SP-A and anti-V5 antibodies, respectively.56 The American Journal of Human Genetics 84, 52–59, January 9, 2by using amonoclonal antibody directed against the c-Myc
epitope. 48 hr after transfection, A549 cells were washed
with ice-cold PBS, scraped on ice in 0.5 ml of freshly
prepared lysis buffer (100 mM NaCl, 50 mM HEPES [pH
7.4], 1.5 mM MgCl2, and 0.5% NP-40 with 1 tablet of
protease cocktail (Roche) per 10ml buffer), and centrifuged
16,0003 g at 4C for 15 min. The supernatants were trans-
ferred to a new tube and incubated with 2 mg of 9E10 mAb
(Santa Cruz Biotechnology) directed against the c-Myc
epitope and 200 mg (20 ml) of a protein A-agarose slurry (Cal-
biochem, San Diego, CA) for 16 hr at 4C. Protein A-bound
antibodies and proteins were separated from the superna-
tant by centrifugation (800 3 g, 15 s) and washed twice
for 10 min in 800 ul of the lysis buffer at 4C. The agarose
pellet was resuspended in 23 Laemli buffer and boiled 5
min prior to SDS-PAGE. Immunoblot analysis of reserved
aliquots of cellular lysate and medium was performed
with anti-Myc (1:1000 dilution of 9E10) or anti-V5 anti-
bodies as described above.
Immunoprecipitation of Myc-tagged wild-type SP-A1 re-
sulted in the coprecipitation of wild-type SP-A2 from both
the cell lysate and the medium (Figure 3B). In contrast to
these results, no V5-tagged SP-A2 G231V or F198S coim-
muniprecipitated with wild-type SP-A1 in the medium,
although they were detected in the cellular lysate. Similar
results were obtained when the Myc-tagged wild-type SP-
A2 was used. Thus, the variants were expressed and inter-
acted with both wild-type SP-A1 and SP-A2 in the cells
but were not secreted into the medium.
To determine whether the mutant forms of SP-A2
(G231Vand F198S) were retained in the endoplasmic retic-
ulum (ER), we subjected aliquots of cellular lysates (25 mg)
or medium (80 mg) to treatment with either Endoglycosi-
dase H or PNGase F (New England Biolabs, Ipswich, MA)
for 1 hr at 37C in the provided buffers. These endoglyco-
sidases differ in their speciﬁcities according to the degree of
maturation of the N-linked sugar chain attached to SP-A2.
Removal of the N-linked sugar results in an ~8 kDa reduc-
tion in the apparent molecular mass of the protein.17
(B) A549 cells transfected with empty vector (Mock), plasmid ex-
pressing the Myc-tagged SP-A1 or SP-A2, and the V5-tagged
wild-type or variant SP-A2. Forty-eight hours after transfection
the cell lysates (C) and medium (M) were split into two aliquots.
The Myc-tagged SP-A proteins were immunoprecipitated from the
cellular lysates and media, subjected to SDS-PAGE, transferred to
nitrocellulose membrane, and immunoblotted with antibodies
directed against the Myc or V5 epitopes (upper panels). The arrow
and arrowhead indicate the position of the Myc-tagged SP-A and
V5-tagged SP-A2, respectively. Aliquots of cell lysates (C) and
medium (M) (40 mg) were subjected to SDS-PAGE, transferred to
nitrocellulose membranes, and immunobloted with antibodies
directed against the Myc or V5 epitopes (lower panels).
(C) A549 cells were transiently transfected with V5-tagged SP-A2
wild-type, G231V, or F198S constructs. Aliquots of lysates (C) or
media (M) were treated with the indicated endoglycosidases and
subjected to immunoblot analysis. Untreated samples were treated
in parallel tubes without the addition of enzyme.009
Analysis of the wild-type and mutant proteins in the cell
lysates revealed a similar reduction in molecular mass after
treatment with PNGase F, which removes all N-linked
sugars, and Endo H, which removes high-mannose sugars
that have not yet undergone complete maturation
(Figure 3C). Thus, all the protein in the cells is located in
the endoplasmic reticulum. In the medium, a reduction
in themolecular mass of the wild-type SP-A2 was seen after
treatment with PNGase F but not Endo H because the
sugars have fully matured coincidently with secretion.
Immunoﬂuorescence of the V5-tagged recombinant
proteins demonstrates colocalization of both the wild-
type SP-A2 and SP-A2 G231V and F198S variants with cal-
nexin, an ER resident protein (data not shown).
These ﬁndings are consistent with a causal relationship
between mutations in SFTPA2 and both IPF and lung
cancer. SFTPA2 is located within the linkage interval for
the disease in a large family with autosomal-dominant
pulmonary ﬁbrosis and adenocarcinoma. An independent
mutation in the same gene was identiﬁed in another
family with an identical phenotype. With two exceptions,
all carriers who were older than age 45 had pulmonary
ﬁbrosis in this family, and several family members also
had adenocarcinoma with BAC features. Neither of these
two mutations was present in any of more than 1000
ethnically matched subjects. Both mutations involve
highly conserved residues and disrupt cellular trafﬁcking
of the protein, probably by interfering with its proper
folding.
Subjects with IPF have a 7- to 14-fold greater risk of
developing lung cancer than those without IPF, and this
risk is not completely accounted for by smoking.18 Hyper-
plasia of type II alveolar cells is frequently seen with IPF,
but case reports of individuals or families with coincident
IPF and BAC are rare.19,20 Development of adenocarci-
noma is believed to involve the multistep progression
from atypical adenomatous epithelial hyperplasia (preneo-
plastic lesion) to BAC and invasive adenocarcinomas.21
The ﬁnding that people who belong to the same family
(F27) and carry a germline SFTPA2 mutation can have
either isolated IPF or IPF with atypical bronchiolar epithe-
lial proliferation, BAC, or adenocarcinoma supports this
paradigm that progenitor cells expressing SP-A are relevant
to the pathogenesis of alveolar-type lung cancer. No other
family in our cohort had multiple individuals with coinci-
dent pulmonary ﬁbrosis and either BAC or adenocarci-
noma with bronchioloalveolar features. The ﬁnding of
both IPF and BAC in the same individuals, especially in
individuals younger than 50 years of age, may be a pheno-
type speciﬁcally associated with SFTPA2 mutations.
Mutations in the collectin mannose-binding protein,
which shares partial structural similarity with SP-A2, are
associated with recurrent pediatric infections.22 We failed
to ﬁnd any evidence that the family members with muta-
tions in SP-A2 have an increased frequency of respiratory
infections. One of the mutation carriers in family F27,
IV:6, was diagnosed at the age of 29 years with hypersensi-Thetivity pneumonitis. She was successfully treated with pred-
nisone and avoidance of birds, the presumed inciting
factor leading to her lung disease. At a molecular level,
transcriptional downregulation of the gene encoding
human SP-A2 is known to be more responsive to the inhib-
itory effects of glucocorticoids than SP-A1.23 The clinical
and pathologic subtype of pulmonary ﬁbrosis for other
mutation carriers in family F27 differ from that of indi-
vidual IV:6. It is unknown whether any of the other muta-
tion carriers might experience a therapeutic beneﬁt from
steroids.
Currently we can only speculate as to how the muta-
tions we identiﬁed in SFTPA2 cause IPF. The accumulation
of misfolded SP-A2 variants may trigger the unfolded
protein response and induce ER stress in the secretory alve-
olar type II cells, as is seen for mutations in the gene that
encodes surfactant protein C (SFTPC).24,25 Mutations in
this gene can cause interstitial lung disease, including
IPF, in pediatric patients and, rarely, adults.26,27 Markers
of elevated ER stress and alveolar epithelial apoptosis
have been demonstrated in sporadic cases of IPF28, and it
is possible that ER stress of type II alveolar cells is
a common feature of IPF. Because alveolar type II cells
can trans-differentiate into alveolar type I cells to repopu-
late the alveolar epithelium after injury29 and express telo-
merase30, a parsimonious hypothesis for the pathogenesis
of familial IPF, resulting frommutations in genes encoding
either surfactant proteins or telomerase, involves alveolar
type II cell dysfunction and an impaired regenerative
capacity of the lung. In addition, the mutations may cause
a pathologic decrease in the secretion of SP-A into the alve-
olar space. Surfactant A has known anti-inﬂammatory
properties31: an alteration in the balance of immunomod-
ulatory regulators in the alveolar space may lead to
increased ﬁbrosis and lung cancer. If this were the case,
then speciﬁc replacement of SP-A or SP-A2 may offer
a potential therapeutic strategy for the treatment of this
lethal disease.
Supplemental Data
Three ﬁgures and four tables are available with this paper online at
http://www.ajhg.org/.
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